CytoDyn has appointed Lauren Wilcoxen as Chief Operating Officer and Head of Regulatory Affairs, effective November 20, 2026.
Wilcoxen will help the clinical-stage oncology company advance its regulatory and clinical development strategy for leronlimab, an investigational humanized monoclonal antibody targeting the CCR5 receptor.
Her immediate priorities will include supporting completion of the Phase 2 CLOVER study in metastatic colorectal cancer and working with the U.S. Food and Drug Administration on the next stages of development.
Regulatory Leadership For Leronlimab
CytoDyn is evaluating leronlimab across oncology indications that include colorectal cancer and triple-negative breast cancer.
The company describes CCR5 as a regulator of immune function that may be relevant across cancer, infectious diseases and autoimmune conditions. However, leronlimab remains investigational, and further clinical testing and regulatory review will be required to determine its safety and effectiveness for any indication.
Wilcoxen has already worked with CytoDyn as a consultant for approximately one year. That experience gave her direct knowledge of its clinical programs and key development decisions before accepting the executive position.
The existing relationship is expected to reduce the time required for her to assume oversight of regulatory planning and operational execution.
Oncology Development Experience
Wilcoxen most recently served as Senior Vice President of Regulatory Affairs at Xilio Therapeutics, a clinical-stage biotechnology company.
From May 2022 until October 2025, she served as Senior Vice President of Product Development and Regulatory Affairs at Checkpoint Therapeutics. During that period, she helped lead a team that secured FDA approval of a checkpoint inhibitor for skin cancer.
Checkpoint Therapeutics was acquired by Sun Pharmaceutical Industries in 2025.
Wilcoxen has also advised public and private biotechnology and pharmaceutical companies on regulatory strategy, clinical development and operations. Much of that work involved complex oncology programs and coordination across clinical, scientific, regulatory and operational teams.
CytoDyn believes her recent experience working with the FDA’s Division of Oncology will be particularly relevant as the company evaluates findings from CLOVER and defines possible future studies.
Connecting Clinical Findings With Regulatory Planning
In her combined role, Wilcoxen will oversee both company operations and regulatory affairs. The structure is intended to connect daily execution with the requirements of the clinical development plan.
Her work will include assessing emerging study data, coordinating internal teams and preparing a regulatory strategy that can be discussed with the FDA.
CytoDyn has characterized findings from CLOVER as encouraging, but the study remains in Phase 2. Early clinical observations do not establish that a drug is safe or effective, and future development will depend on complete data, regulatory feedback and potentially additional trials.
Wilcoxen holds Regulatory Affairs Certification from the Regulatory Affairs Professionals Society. She earned a doctorate in microbiology and immunology from the University of North Carolina at Chapel Hill and a bachelor’s degree in biology from Mount Saint Mary’s University.
She also serves on the boards of the American Cancer Society and Caring Community Foundation.
KEY QUOTES:
Lauren’s appointment comes at an important time for CytoDyn as we continue to advance our oncology development strategy and build on emerging findings from our CLOVER study. Her extensive regulatory expertise, recent success working with the FDA’s Division of Oncology, and firsthand knowledge of our clinical programs make her exceptionally well suited to help guide CLOVER through the completion of Phase 2 and shape our regulatory strategy for the next stages of leronlimab’s development. We are pleased to welcome her to our executive leadership team.
Robert E. Hoffman, CEO of CytoDyn
Having worked closely with CytoDyn over the past year, I have developed a strong understanding of leronlimab’s scientific rationale, the CLOVER study, and the opportunities ahead for the Company’s oncology programs. I am encouraged by the emerging clinical findings and look forward to working with the team to translate these insights into a clear, rigorous regulatory and clinical development strategy. Our priority will be to work closely with the FDA to define a clear regulatory strategy that supports leronlimab’s continued clinical development.
Lauren Wilcoxen, Chief Operating Officer and Head of Regulatory Affairs at CytoDyn

